IFRX Share Price | InflaRx NV Stock Analysis & Recommendation

Q: How big is InflaRx NV?

Market Cap: As of Jun 18, InflaRx NV has a market capitalization of 51.69 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, InflaRx NV reported net sales of 0.19 million and a net profit of -53.31 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 63.60 million and total assets of 78.72 million.

Q: What does InflaRx NV do?

Overview: InflaRx NV is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for the treatment of life-threatening inflammatory diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) Market cap: USD 51.69 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.93 Return on Equity: -70.03% Price to Book: 0.68Contact Details: Address: Winzerlaer Str. 2, JENA None: 07745 Tel: 49 3641 508180 Website: https://www.inflarx.de/

Q: Is InflaRx NV technically bullish or bearish?

As of 8 September 2025, the technical trend for InflaRx NV has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, and weekly Dow Theory also showing a mildly bearish outlook. While the MACD is mildly bullish on both weekly and monthly timeframes, the overall sentiment is tempered by the bearish signals from Bollinger Bands and KST on the monthly timeframe. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -44.53% compared to the S&P 500's 12.22%, highlighting its weak performance over multiple periods.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

684.73 k

Shareholding (Sep 2025)

FII

1.30%

Held by 12 FIIs

DII

98.33%

Held by 3 DIIs

Promoter

0.00%

How big is InflaRx NV?

22-Jun-2025

As of Jun 18, InflaRx NV has a market capitalization of 51.69 million, with net sales of 0.19 million and a net profit of -53.31 million over the latest four quarters. The company reported shareholder's funds of 63.60 million and total assets of 78.72 million as of Dec 24.

View full answer

What does InflaRx NV do?

22-Jun-2025

InflaRx NV is a clinical-stage biopharmaceutical company developing monoclonal antibodies for life-threatening inflammatory diseases, with a market cap of $51.69 million and a recent net profit of -$9 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

View full answer

Is InflaRx NV technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, InflaRx NV's trend is mildly bearish, influenced by bearish daily moving averages and weekly Dow Theory, despite a mildly bullish MACD; it has significantly underperformed the S&P 500 with a year-to-date return of -44.53%.

View full answer

Compare InflaRx NV with Similar Stocks

Harpoon Therapeutics, Inc.Selecta Biosciences, Inc.Gritstone bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 67 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.98

Return on Equity

-116.85%

Price to Book

1.26

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-16 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-30.64%

6 Months

-66.98%

1 Year

-47.76%

2 Years

-80.16%

3 Years

-41.87%

4 Years

-73.8%

5 Years

-88.75%

InflaRx NV for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.54%

EBIT Growth (5y)

-0.43%

EBIT to Interest (avg)

-57.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.93

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

35.68%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.73

EV to EBIT

0.24

EV to EBITDA

0.25

EV to Capital Employed

-2.77

EV to Sales

-14.98

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-70.03%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.38%)

Foreign Institutions

Held by 12 Foreign Institutions (1.3%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -86.36% vs 54.17% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.60",
          "val2": "-14.10",
          "chgp": "-10.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.00",
          "val2": "6.40",
          "chgp": "-84.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.40",
          "val2": "-8.80",
          "chgp": "-86.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-351,387.80%",
          "val2": "0.00%",
          "chgp": "-35,138.78%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 100.00% vs 0.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.03% vs -48.71% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-62.50",
          "val2": "-62.20",
          "chgp": "-0.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.50",
          "val2": "14.20",
          "chgp": "-61.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.80",
          "val2": "-46.10",
          "chgp": "-8.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-351,628.80%",
          "val2": "-921,291.50%",
          "chgp": "56,966.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-15.60

-14.10

-10.64%

Interest

0.00

Exceptional Items

1.00

6.40

-84.38%

Consolidate Net Profit

-16.40

-8.80

-86.36%

Operating Profit Margin (Excl OI)

-351,387.80%

0.00%

-35,138.78%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -86.36% vs 54.17% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.20

0.10

100.00%

Operating Profit (PBDIT) excl Other Income

-62.50

-62.20

-0.48%

Interest

0.00

Exceptional Items

5.50

14.20

-61.27%

Consolidate Net Profit

-49.80

-46.10

-8.03%

Operating Profit Margin (Excl OI)

-351,628.80%

-921,291.50%

56,966.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 100.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.03% vs -48.71% in Dec 2023

All Annual Results

Company CV

About InflaRx NV

InflaRx NV

Pharmaceuticals & Biotechnology

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Company Coordinates

Company Details

Winzerlaer Str. 2 , JENA None : 07745

Tel: 49 3641 508180

https://www.inflarx.de/

Registrar Details

InflaRx NV

1Day

52 Week

CASH

FII

DII

Promoter

How big is InflaRx NV?

Watch in Real-Time

What does InflaRx NV do?

Is InflaRx NV technically bullish or bearish?

Compare InflaRx NV with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About InflaRx NV

Company Coordinates